Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in oncology and auto-immune disease indications. The company’s drug products use our proprietary recombinant human alpha fetoprotein (AFP) with unique immuno-oncology properties. ACT has exclusive worldwide rights to the targeted delivery platform Alpha Fetoprotein with over $100 million spent on the development of the in-licensed technology. Clinical studies of AFP have demonstrated safety in over 300 patients and established a robust Drug Master file with the FDA including manufacturing, toxicology, and human safety.
Aphios, is researching and developing anticancer therapeutics and supportive care drugs from medicinal plants and marine organisms based on the company's enabling technology platforms of drug discovery, manufacturing and delivery. Aphios' goal is to develop therapies to treat cancer as a chronic rather than acute disease, provide the less toxic and mostly plant-based natural drugs such as nanoformulations of Taxol® and Taxotere® that can be used in an acute setting until long-term preventative solutions can be developed, and to provide supportive care for cancer patients undergoing acute treatment.
Aurora Biopharma, Inc., a biopharmaceutical company, develops therapies for solid tumor cancers. The company develops chimeric antigen receptor (CAR) T cells, a therapy in which cancer patients blood is withdrawn and their T cell is extracted from their white blood cells, genetically edited to express a CAR specific to that type of cancer cell, and re-infused back to the patient to target and kill cancer cells. Its platform targets main and co-stimulatory solid tumor associated antigens present on a range of solid tumor cancers, starting with brain tumors, sarcomas, and breast cancers.
CEL-SCI is a Phase 3 cancer immunotherapy company. The Phase 3 study is fully enrolled with 928 patients. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient’s immune system while it is still intact in order to have the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with head and neck cancer with its lead investigational immunotherapy Multikine (Leukocyte Interleukin, Injection), BEFORE they have received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are used only after conventional therapies have been tried and/or failed. Head and neck cancer represents about 6% of all cancers. Multikine has received Orphan Drug designation from the FDA for the treatment of head and neck cancer patients with advanced squamous cell carcinoma. CEL-SCI has received patents for Multikine from the US, Europe, China and Japan.
The Company’s LEAPS technology is being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the National Institutes of Health. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
Cible is a preclinical-stage cancer drug company that solves the major problems of traditional cancer therapy
through the implementation of a smart drug platform. The first lead candidate, oxaliTEX, is found to be well tolerated, tumor localizing, and overcomes platinum drug resistance in pharmacological in vitro human cancer models. These attributes have high value in multiple indications that do not respond to platinum or biologicals, such as immunotherapies.
CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ tunable linker technologies to provide targeted delivery, release and accumulation of the cytotoxic drug payloads at the tumor site. CytRx is rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.
CytRx's innovative LADR™ (Linker Activated Drug Release) technology employs a broad portfolio of novel linker molecules that selectively bind to circulating albumin and can be linked to a wide variety of anti-cancer payloads. The Company trades on the Nasdaq exchange under the ticker CYTR.
Geneius is a private biopharmaceutical company run by the Former CEO of Bluebird Bio focused on the discovery and clinical development of adoptive T cell therapy products that address the treatment of cancer and infections. The company has created a good manufacturing process, or GMP, for the production of T cells from peripheral blood for infusion into the patient, allowing for manufacturing at a price of 1/10th that of traditional CAR-T. Geneius' targeted DiversiTy™ platform is a novel ex vivo approach that re-educates T cells to become responsive to multiple, previously overlooked tumor antigens. Geneius' lead product candidate, GNS-TEBV-001, is currently in preclinical testing for EBV+, NHL, gastric and nasopharyngeal cancers. Geneius also has two additional products, GNS-TGBM-002 and GNS-TPC-003, in preclinical testing for glioblastoma and pancreatic cancer, respectively.
Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology. The company's proprietary TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most vaccine and therapeutic approaches. Hookipa’s vectors are not impeded by vector-neutralizing antibodies and can be administered repeatedly, providing even greater immune protection. Levels of specific T cells generated by TheraT® are unprecedented in the field and have the potential to transform active immune-therapy in cancers.
Immix Biopharma, Inc. develops novel therapies for cancer patients. The company’s products include Imx-110 which is a nanoparticle delivery vehicle, co-loaded with small doses of cytotoxin and a potent agent that has shown synergy with multiple cytotoxic agents, such as doxorubicin, paclitaxel, carboplatin, PD1 inhibitors, T Cell therapies, and radiation; and Imx-111 which is a targeted form of Imx-110. Further, the company develops multi-component drug candidates. Immix Biopharma, Inc. primarily caters to chemotherapy and immunotherapy-resistant patients.
Immunicom has leveraged the latest, cutting-edge clinical research in immune regulatory pathways and their role in cancer and autoimmune disease to develop a revolutionary immunotherapy platform (Immunopheresis™) for treating cancer and other terminal diseases through a BLOOD FILTERING DEVICE. We filter a patient’s blood of "blocking proteins" released by cancer cells that suppress the immune system. Once these proteins are removed, the immune system naturally attacks the tumor and cancer. Immunicom is led by Amif Jafri, the Former Head of R&D of Cardinal Health. The company first target is STNFr.
ImmunoCellular is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors.
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary antibody drug conjugate (ADC) platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. Mersana’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
NED Biosystems is a biotechnology company developing an advanced, fast-to-market oral combination therapy to treat multiple cancer indications. Our lead therapeutic candidate, NED-170, simultaneously targets five key processes that drive survival and growth of all advanced cancer. This multi-pronged approach has proven effective in some of humanity’s most intractable diseases and helps prevent the "breakthrough" (limited durability of effect) seen with many more narrowly targeted cancer treatment approaches, and at the same time prioritizes high patient quality of life.
OTraces has developed a disruptive technology using math/physics-based noise suppression techniques to enhance the
accuracy and performance of cancer diagnostics. By using these techniques to access the active proteins found in the
tumor microenvironment (TME) with, for the first time, simple and cost-effective blood based-tests, OTraces has solved
the problem of deciphering biomarker activity within the TME, which has come to be recognized and accepted in science as a vast storehouse of diagnostic content exceeding the tumor itself. It is the only blood test known to determine tumor
status and progression.
RadImmune Therapeutics is a private biotechnology company about to enter the clinic with its first product. Radimmune is pioneering innovative therapies via its proprietary antibody drug conjugation (ADC) and antibody radio-conjugation (ARC) platform for melanoma, pancreatic and additional cancer types. Radimmune currently has three pre-clinical programs in oncology and expects to launch a Phase 1 trial in melanoma (cutaneous, acral and uveal) by year-end 2018 and a Phase 1 trial in pancreatic cancer in 2019. RadImmune is led by an experienced management team that has both taken companies public and led successful oncology clinical development programs.
A major unmet need in oncology today is the inability to assess quickly which patients are responding to medications, and which patients are not. This leads to delays in effective care, over-treatment, unnecessary toxicities and over $60 billion in waste every year. Rna Diagnostics has developed the RNA Disruption Assay (RDA) to address this major unmet need. RDA tells oncologists, within the first 2-3 weeks of treatment, if a patient's tumor is responding to the drugs prescribed or not. RDA will enable a revolution in oncology care: response guided cancer treatment. If a patient is not responding, the doctor can move on to the next best alternative, surgery, radiation, or different drugs. This approach will improve survival, reduce unnecessary toxicity, and save healthcare systems money.
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune cells, such as T-lymphocytes that are isolated from the patient or retrieved from allogeneic immune cell banks, and then expanded and in some cases processed to express tumor-binding receptors. Our approach introduces a new and important step in ex-vivo processing of the immune cells where sd-rxRNA is used to eliminate the expression of immunosuppressive receptors or proteins from the therapeutic immune cells, making them less sensitive to tumor resistance mechanisms and thus improving their ability to destroy the tumor cells. Essentially, we aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer and ultimately provide patients battling terminal cancers with a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.rxipharma.com.
SageMedic is creating a 3D micro-tumor assay to help physicians determine the best cancer treatment for their patient. To do so, we take a live tumor biopsy, create hundreds of 3D micro-tumors, expose them to a wide range of anti-cancer drugs (e.g. chemotherapy or targeted therapy), and measure the response to identify the most effective treatment that will be communicated with the treating oncologist.
SciTech Development, LLC is a clinical stage, biopharmaceutical company that converted fenretinide, an underperforming yet proven anticancer agent, into a fully functional intravenous (IV) drug for the treatment of numerous cancers. SCI’s clinical lead compound, ST-001, is a short-development track anticancer agent delivered in a novel nanoparticle-based system. Fenretinide has shown clinical, targeted cancer destroying activity and, when combined with SCI’s new, patented, nanoparticle delivery system, promises to save many lives. Initially, it was clinically tested and shown to be safe in a breast cancer prevention trial of more than 3,000 women. It later evolved into a cancer therapeutic and was shown to be effective in treating many other cancers. Development of fenretinide was hindered by low active drug concentrations and by the side effects associated with poorly designed IV delivery systems. ST-001 overcomes those problems by delivering greater concentrations safely at the required dose levels. It will initially target T-cell lymphoma and small cell lung cancer followed by broader market opportunities that include leukemia, breast, ovarian, lung, pancreatic, prostate, renal cell and other cancers previously shown to respond to fenretinide.
Soligenix, Inc., a late-stage, public biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn’s disease and acute radiation enteritis.
TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. It specializes in the development of immunotherapies targeting women’s cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers. The company’s peptide-or nucleic acid-based immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient’s killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. It also focuses on developing PolyStart, a DNA expression technology, which is in pre-clinical stage to enhance the ability of the cellular immune system to recognize and destroy diseased cells.
TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.
Tosk is a dynamic drug development company dedicated to alleviating the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call CompanionTM drugs that, when administered alongside certain cancer therapies, such as methotrexate, doxorubicin, cisplatin, EGFR inhibitors, and radiation — what we call parent therapies — will significantly improve patient outcomes.
Trethera is a clinical-stage biopharmaceutical company developing cancer treatments for orphan blood cancers with high unmet needs. The Company is led by an experienced drug development team and was founded by highly recognized UCLA faculty successful in bringing medical products to market. Focusing on the pathways controlling cancer nucleotide metabolism led to the development of TRE-515, a first-in-class inhibitor of deoxycytidine kinase (dCK) that is targeted to enter a Phase 1 clinical study in H1 2018.
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development. By leveraging this expertise and combining it with advanced machine learning and data analytics, new tests are being released which substantially improve the accuracy of biomarker blood tests for the early detection of cancers. This unique approach, being pioneered by 20/20, results in affordable, highly accurate cancer blood tests.
Vitanova Biomedical Incorporated (VNB) is a private San Antonio, Texas-based early-stage biotechnology company focusing on the development and implementation of proprietary intellectual property that has proven successful in killing cancer in vitro (in a petri dish). Currently, we are conducting pre-clinical trials utilizing our proprietary light-activated acidosis therapy to treat and kill multiple types of aggressive cancer cells, and have secured our CRO (Clinical Research Organization) partner (Cancer Insight, San Antonio, TX) to conduct our Phase I through Phase III clinical testing.
Volition is a multi-national, publically-traded, life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition’s initial Nu. Q™ products are focusing on colorectal cancer. Colorectal cancer is ranked second among all newly diagnosed cancers.